Breast Cancer Research and Treatment

Breast Cancer Research and Treatment is a comprehensive forum for research on breast cancer, published by Springer and running for more than forty years.《乳腺癌研究与治疗》是研究乳腺癌的综合性园地，由 Springer 出版，已运行四十余年。

Its scope stretches across surgery, radiotherapy, medical oncology, endocrinology, epidemiology, immunology and cell biology.其范围横跨外科学、放射治疗、内科肿瘤学、内分泌学、流行病学、免疫学与细胞生物学。

In the 2025 edition of the journal citation report it holds an impact factor of 3.3 and stands in the second quartile of oncology.在 2025 年版期刊引证报告中，该刊的影响因子为 3.3，在肿瘤学类目中列第二区。

Scope

• The journal takes every aspect of breast cancer research as its subject, from the laboratory bench through to the clinic.该刊把乳腺癌研究的方方面面都纳入选题，自实验室工作台一直延伸到临床。

• Surgery belongs to the scope, and the journal carries work on the operative treatment of the breast and of the axilla.外科学属于收稿范围，该刊刊载乳腺与腋窝手术治疗方面的研究。

• Radiotherapy is covered, and studies of dose, technique and the sequencing of treatment with other modalities are admitted.放射治疗得到覆盖，关于剂量、技术以及与其他手段排序的研究也在接纳之列。

• Medical oncology forms a central strand, and papers on systemic treatment and its effects are regular fare.内科肿瘤学构成中心支线，关于全身治疗及其效果的论文是常见内容。

• Endocrinology is treated as a subject of its own, and the journal follows the hormonal pathways that drive some tumours.内分泌学自成一个选题，该刊追踪驱动某些肿瘤的激素通路。

• Epidemiology supplies a large share of the content, and the journal reports on incidence, risk factors and outcomes in populations.流行病学贡献了相当大一部分内容，该刊报道人群中的发病、危险因素与结局。

• Immunology is admitted, and work on the immune response to the disease and on immune based treatment is taken.免疫学也在接纳之列，关于机体对该病的免疫应答以及免疫治疗的工作受到收载。

• Cell biology forms part of the scope, and studies of the mechanisms that underlie tumour growth and spread are welcomed.细胞生物学是收稿范围的一部分，关于肿瘤生长与扩散机制的考察受到欢迎。

• The journal sets out to disseminate the latest research, and it seeks to publish findings that bear on clinical practice.该刊意在传播最新研究，并力求发表对临床实践有所影响的发现。

• Ongoing controversies in the treatment of breast cancer are given room, and opposing views may be set out in its pages.乳腺癌治疗中持续存在的争议在刊物中得到空间，不同意见可以在此陈说。

• Management guidelines are published, so that clinicians have a reference for the standards of care.该刊刊载管理指南，从而在诊疗标准方面充当参考。

• Translational work that carries a laboratory finding towards the patient is treated as a priority.把实验室发现推向患者的转化性工作被视为优先。

• A wide audience of researchers and professionals is addressed, spanning oncology, surgery, radiology and nursing research.该刊面向广泛的研究者与专业人员，涵盖肿瘤学、外科、放射学与护理研究。

• A paper may address the pathology of a tumour, the imaging that reveals it or the reconstruction that follows its removal.一篇论文可以讨论肿瘤的病理、揭示它的影像，或切除之后的修复重建。

• Screening and early detection belong to the scope, and the journal carries work on mammography and on other means of finding a tumour early.筛查与早期发现属于收稿范围，该刊刊载乳腺摄影以及其他早期发现手段的研究。

• Work on the molecular subtypes of breast cancer is admitted, and the differences in behaviour between them are a running theme.乳腺癌分子亚型的工作受到收载，各亚型行为上的差异是持续出现的主题。

• Treatment for metastatic disease is treated at length, and the journal follows the sequence in which lines of therapy are given.转移性疾病的治疗得到细致处理，该刊追踪各线治疗的先后顺序。

• Supportive care and survivorship are covered, and the journal takes papers on the long term effects of treatment.支持性照护与长期生存得到覆盖，该刊收载治疗远期影响方面的论文。

• Pathology and molecular diagnostics are part of the subject, and studies that link a marker to a decision about treatment are welcome.病理学与分子诊断是选题的一部分，把标志物与治疗决策联系起来的考察受到欢迎。

• The journal prints reviews from time to time, and a review is expected to weigh the evidence rather than to set it out mechanically.该刊不时刊载综述，所选综述要求权衡证据，而非机械地罗列。

History

• The first volume appeared in 1981, published from The Hague and Boston by Martinus Nijhoff.第 1 卷于 1981 年问世，由 Martinus Nijhoff 在海牙与波士顿出版。

• In later years the imprint moved to Dordrecht, where Kluwer Academic took over the title before it passed to Springer.后来出版信息转到多德雷赫特，Kluwer Academic 在那里接手该刊，其后又归入 Springer。

• The journal now runs to eighteen issues a year, spread across several volumes with three issues apiece.该刊如今每年出版十八期，分属数卷，每卷各三期。

• The print number is 0167-6806 and the electronic number is 1573-7217.印刷版编号为 0167-6806，电子版编号为 1573-7217。

• MEDLINE and PubMed have indexed the title from the first volume of 1981, and it also appears in Index Medicus.MEDLINE 与 PubMed 自 1981 年的第 1 卷起收录该刊，它也见于 Index Medicus。

• The impact indicator has moved from 4.872 and 4.624 to 3 and 3, and it stood at 3.3 in the 2025 edition.影响因子从 4.872 与 4.624 变为 3 与 3，在 2025 年版为 3.3。

• The journal is a hybrid title, publishing on subscription while allowing authors to pay for open access to a paper.该刊是混合刊，以订阅方式出版，同时允许作者付费让自己的论文开放获取。

• More than forty years of continuous publication lie behind the present volume, and the editors describe the title as a reliable resource for a wide audience.当前各卷背后是四十余年的连续出版，编辑方把该刊描述为面向广大读者的可靠资源。

• A series of editorial appointments has been recorded in recent years, and new members have been introduced to the team.近年来该刊记录了一系列编辑任命，新成员陆续进入团队。

• The journal has added open calls for papers, and collections on cancer disparities and on liquid biopsy were opened for submissions.该刊增设了公开征稿，围绕癌症差异与液体活检的专题集已开放投稿。

• The publisher keeps the title within its medical list, and the journal's materials are distributed through the same platform as its sibling oncology titles.出版方把该刊保留在其医学刊群之内，刊物材料与其姊妹肿瘤学期刊通过同一平台分发。

• The journal has carried position pieces and guidelines from professional bodies alongside its research papers.该刊在研究论文之外也刊载专业团体的立场文章与指南。

• Special collections have been gathered on topics such as cancer disparities and the use of liquid biopsy in breast cancer.该刊围绕癌症差异与乳腺癌液体活检等题目汇集专题集。

• Papers drawn from registries and from large cohorts appear regularly, and the journal follows the outcomes of defined groups of patients over time.来自登记库与大型队列的论文定期出现，该刊追踪特定患者群体的长期结局。

Editors

• The editor-in-chief is Aditya Bardia, who leads the editorial team.主编是（Aditya Bardia），由他带领编辑团队。

• The journal is recruiting an associate editor to support the peer review process, with a start date set for January 2027.该刊正在招募一位副编辑以支持同行评审流程，起始时间定在 2027 年 1 月。

• An editorial board covers the disciplines that the journal serves, from surgery and medical oncology to epidemiology and cell biology.编委会覆盖该刊服务的各学科，自外科与内科肿瘤学延伸至流行病学与细胞生物学。

• Manuscripts are submitted through the publisher's online system and are sent to external referees for peer review.稿件通过出版方的在线系统投递，并送交外部审稿人进行同行评审。

• The median time from submission to a first decision is given as nine days, and the journal publishes the figure in its metrics.从投稿到首次决定的中位时长记为九天，该刊把这一数字公布在其指标栏中。

• Two forms of open access are available, and authors may choose between publication on subscription and paying for immediate free access.该刊提供两种开放获取方式，作者可在订阅出版与付费即时免费阅读之间选择。

• Submissions are expected to conform to the journal's guidelines, and the publisher provides a pre-submission checklist.来稿须符合该刊的投稿指南，出版方还提供投稿前检查清单。

• The editorial team works with collections editors on themed issues, and open collections remain open for submission over an extended period.编辑团队与专题编辑合作筹办主题期，开放的专题集在较长时期内持续征稿。

• Authors are asked to declare competing interests, and the journal follows the publisher's ethics and disclosure policies.作者须声明利益冲突，该刊遵循出版方的伦理与披露政策。

• The journal lists its abstracting services, among them the clinical and life sciences current contents, Medline, Embase and Scopus.该刊列明其文摘服务，其中包括临床与生命科学现刊目次、Medline、Embase 与 Scopus。